Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells $2,287,227.60 in Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold a total of $2,287,227.60 worth of stock, reducing its position by 5.61%.
• Vor Biopharma's stock price has experienced significant volatility, with a one year low of $2.62 and a high of $65.80.
• Wall Street analysts have mixed opinions on Vor Biopharma, with ratings ranging from "strong buy" to "strong sell", and a consensus price target of $77.83.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 71,655 shares of the company's stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $31.92, for a total value of $2,287,227.60. Following the sale, the insider owned 1,206,463 shares in the company, valued at $38,510,298.96. The trade was a 5.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The stock was sold at an average price of $30.45, for a total value of $61,539.45.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total value of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The shares were sold at an average price of $32.44, for a total value of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The shares were sold at an average price of $30.97, for a total transaction of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total transaction of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The stock was sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The stock was sold at an average price of $39.83, for a total value of $1,292,523.33.

Vor Biopharma Price Performance

NASDAQ:VOR traded down $0.06 on Friday, hitting $29.00. The company's stock had a trading volume of 613,740 shares, compared to its average volume of 395,121. Vor Biopharma Inc. has a one year low of $2.62 and a one year high of $65.80. The company has a market cap of $198.65 million, a price-to-earnings ratio of -0.11 and a beta of 2.07. The firm has a fifty day moving average of $36.55.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Investors Weigh In On Vor Biopharma

A number of large investors have recently added to or reduced their stakes in VOR. Money Concepts Capital Corp raised its holdings in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in Vor Biopharma during the second quarter worth about $66,000. OMERS ADMINISTRATION Corp bought a new position in Vor Biopharma in the 1st quarter valued at about $100,000. Finally, Jane Street Group LLC acquired a new position in shares of Vor Biopharma in the 1st quarter valued at approximately $140,000. Institutional investors and hedge funds own 97.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Robert W. Baird raised shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $20.00 to $64.00 in a research report on Wednesday. Wall Street Zen cut shares of Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. Baird R W upgraded shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Wednesday. Stifel Nicolaus raised Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price on the stock in a research report on Wednesday, September 24th. Finally, Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $77.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.